Skip to main content
Top
Published in: Diabetes Therapy 2/2013

Open Access 01-12-2013 | Review

Adherence to Therapies in Patients with Type 2 Diabetes

Authors: Luis-Emilio García-Pérez, María Álvarez, Tatiana Dilla, Vicente Gil-Guillén, Domingo Orozco-Beltrán

Published in: Diabetes Therapy | Issue 2/2013

Login to get access

Abstract

Adherence to therapy is defined as the extent to which a person’s behavior in taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a healthcare provider. Patients presenting with type 2 diabetes mellitus are initially encouraged to maintain a healthy diet and exercise regimen, followed by early medication that generally includes one or more oral hypoglycemic agents and later may include an injectable treatment. To prevent the complications associated with type 2 diabetes, therapy frequently also includes medications for control of blood pressure, dyslipidemia and other disorders, since patients often have more than three or four chronic conditions. Despite the benefits of therapy, studies have indicated that recommended glycemic goals are achieved by less than 50% of patients, which may be associated with decreased adherence to therapies. As a result, hyperglycemia and long-term complications increase morbidity and premature mortality, and lead to increased costs to health services. Reasons for nonadherence are multifactorial and difficult to identify. They include age, information, perception and duration of disease, complexity of dosing regimen, polytherapy, psychological factors, safety, tolerability and cost. Various measures to increase patient satisfaction and increase adherence in type 2 diabetes have been investigated. These include reducing the complexity of therapy by fixed-dose combination pills and less frequent dosing regimens, using medications that are associated with fewer adverse events (hypoglycemia or weight gain), educational initiatives with improved patient–healthcare provider communication, reminder systems and social support to help reduce costs. In the current narrative review, factors that influence adherence to different therapies for type 2 diabetes are discussed, along with outcomes of poor adherence, the economic impact of nonadherence, and strategies aimed at improving adherence.
Literature
1.
go back to reference Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443–53.PubMedCrossRef Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443–53.PubMedCrossRef
2.
go back to reference International Diabetes Federation. Diabetes and impaired glucose tolerance. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2012. International Diabetes Federation. Diabetes and impaired glucose tolerance. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2012.
3.
go back to reference King DE, Mainous AG, Carnemolla M, Everett CJ. Adherence to healthy lifestyle habits in US adults, 1988–2006. Am J Med. 2009;122:528–34.PubMedCrossRef King DE, Mainous AG, Carnemolla M, Everett CJ. Adherence to healthy lifestyle habits in US adults, 1988–2006. Am J Med. 2009;122:528–34.PubMedCrossRef
4.
go back to reference Vivian EM. Type 2 diabetes in children and adolescents—the next epidemic? Curr Med Res Opin. 2006;22:297–306.PubMedCrossRef Vivian EM. Type 2 diabetes in children and adolescents—the next epidemic? Curr Med Res Opin. 2006;22:297–306.PubMedCrossRef
5.
go back to reference American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11–66.CrossRef American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11–66.CrossRef
6.
go back to reference Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med. 2004;164:1134–9.PubMedCrossRef Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med. 2004;164:1134–9.PubMedCrossRef
7.
go back to reference World Health Organization: Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003. World Health Organization: Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
9.
go back to reference Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.PubMedCrossRef Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.PubMedCrossRef
10.
go back to reference Guillausseau P-J. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol. 2005;4:167–75.PubMedCrossRef Guillausseau P-J. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol. 2005;4:167–75.PubMedCrossRef
11.
go back to reference Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–35.PubMedCrossRef Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–35.PubMedCrossRef
12.
go back to reference Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–8.PubMedCrossRef Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–8.PubMedCrossRef
13.
go back to reference Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84.PubMedCrossRef Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84.PubMedCrossRef
14.
go back to reference Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44:1640–61.PubMedCentralPubMedCrossRef Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44:1640–61.PubMedCentralPubMedCrossRef
15.
go back to reference Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.PubMedCrossRef Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.PubMedCrossRef
16.
go back to reference Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8–15.PubMedCrossRef Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8–15.PubMedCrossRef
17.
go back to reference Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65:314–22.PubMedCrossRef Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65:314–22.PubMedCrossRef
18.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.PubMedCrossRef
20.
go back to reference Praet SF, van Rooij ES, Wijtvliet A, et al. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2008;51:736–46.PubMedCentralPubMedCrossRef Praet SF, van Rooij ES, Wijtvliet A, et al. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2008;51:736–46.PubMedCentralPubMedCrossRef
21.
go back to reference Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care. 2006;29:2586–91.PubMedCrossRef Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care. 2006;29:2586–91.PubMedCrossRef
22.
go back to reference Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun. 2001;6:99–115.CrossRef Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun. 2001;6:99–115.CrossRef
23.
go back to reference Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71–5.PubMed Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71–5.PubMed
24.
go back to reference Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.PubMedCrossRef Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.PubMedCrossRef
25.
go back to reference Guillausseau P-J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes: a survey in general practice. Diabetes Metab. 2003;29:79–81.PubMedCrossRef Guillausseau P-J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes: a survey in general practice. Diabetes Metab. 2003;29:79–81.PubMedCrossRef
26.
go back to reference Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24.PubMedCentralPubMedCrossRef Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24.PubMedCentralPubMedCrossRef
27.
go back to reference Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733–5.PubMedCentralPubMedCrossRef Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733–5.PubMedCentralPubMedCrossRef
28.
go back to reference Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–50. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–50.
29.
go back to reference Yurgin NR, Boye KS, Dilla T, Suriñach NL, Llach XB. Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence. 2008;2:87–95.PubMedCentralPubMed Yurgin NR, Boye KS, Dilla T, Suriñach NL, Llach XB. Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence. 2008;2:87–95.PubMedCentralPubMed
30.
go back to reference Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMedCrossRef Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.PubMedCrossRef
31.
go back to reference Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–45.PubMed Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–45.PubMed
32.
go back to reference Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25:850–5.PubMedCrossRef Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25:850–5.PubMedCrossRef
33.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMedCrossRef
34.
go back to reference Mateo JF, Gil-Guillén VF, Mateo E, Orozco D, Carbayo JA, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422–8.PubMedCrossRef Mateo JF, Gil-Guillén VF, Mateo E, Orozco D, Carbayo JA, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422–8.PubMedCrossRef
35.
go back to reference Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47:334–41.PubMedCentralPubMedCrossRef Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47:334–41.PubMedCentralPubMedCrossRef
36.
go back to reference Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791–9.PubMedCrossRef Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791–9.PubMedCrossRef
37.
go back to reference Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231–8.PubMedCrossRef Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231–8.PubMedCrossRef
38.
go back to reference Dilla T, Costi M, Boye KS, et al. The impact of obesity in the management and evolution of diabetes mellitus. Rev Clin Esp. 2008;208:437–43.PubMedCrossRef Dilla T, Costi M, Boye KS, et al. The impact of obesity in the management and evolution of diabetes mellitus. Rev Clin Esp. 2008;208:437–43.PubMedCrossRef
39.
go back to reference Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–12.PubMedCrossRef Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–12.PubMedCrossRef
40.
go back to reference Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79–88.PubMedCrossRef Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79–88.PubMedCrossRef
41.
go back to reference Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation. 2009;119:351–7.PubMedCrossRef Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation. 2009;119:351–7.PubMedCrossRef
42.
go back to reference Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416–24.PubMedCrossRef Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416–24.PubMedCrossRef
43.
go back to reference Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338–42.PubMedCrossRef Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338–42.PubMedCrossRef
44.
go back to reference Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Prac. 2010;87:204–10.CrossRef Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Prac. 2010;87:204–10.CrossRef
45.
go back to reference Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011;34:338–40.PubMedCentralPubMedCrossRef Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011;34:338–40.PubMedCentralPubMedCrossRef
46.
go back to reference Farmer A, Kinmonth AL, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med. 2006;23:265–70.PubMedCrossRef Farmer A, Kinmonth AL, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med. 2006;23:265–70.PubMedCrossRef
47.
go back to reference Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes. 2010;4(Suppl 1):S11–8.PubMedCrossRef Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes. 2010;4(Suppl 1):S11–8.PubMedCrossRef
48.
go back to reference Woudenberg YJ, Lucas C, Latour C. Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802.PubMedCrossRef Woudenberg YJ, Lucas C, Latour C. Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802.PubMedCrossRef
49.
go back to reference Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–7.PubMedCrossRef Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–7.PubMedCrossRef
50.
go back to reference Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34:692–7.PubMedCrossRef Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34:692–7.PubMedCrossRef
51.
go back to reference Tiv M, Viel J-F, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS ONE. 2012;7:e32412.PubMedCentralPubMedCrossRef Tiv M, Viel J-F, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS ONE. 2012;7:e32412.PubMedCentralPubMedCrossRef
52.
go back to reference Doggrell SA. Does intervention by an allied health professional discussing adherence to medicines improve this adherence in type 2 diabetes? Diabet Med. 2010;27:1341–9.PubMedCrossRef Doggrell SA. Does intervention by an allied health professional discussing adherence to medicines improve this adherence in type 2 diabetes? Diabet Med. 2010;27:1341–9.PubMedCrossRef
53.
go back to reference Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educ. 2009;35:72–96.PubMedCrossRef Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educ. 2009;35:72–96.PubMedCrossRef
54.
go back to reference Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
55.
go back to reference Ciechanowski PS, Katon WJ, Russo JE, Walker EA. The patient–provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry. 2001;158:29–35.PubMedCrossRef Ciechanowski PS, Katon WJ, Russo JE, Walker EA. The patient–provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry. 2001;158:29–35.PubMedCrossRef
56.
go back to reference Rubin RR, Peyrot M, Simnerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29:1149–55.CrossRef Rubin RR, Peyrot M, Simnerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29:1149–55.CrossRef
57.
go back to reference Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.PubMedCrossRef Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.PubMedCrossRef
58.
go back to reference Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84.PubMedCentralPubMedCrossRef Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84.PubMedCentralPubMedCrossRef
59.
go back to reference Dall T, Zhang Y, Chen Y, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29:297–303.CrossRef Dall T, Zhang Y, Chen Y, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29:297–303.CrossRef
60.
go back to reference Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300–4.PubMedCrossRef Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300–4.PubMedCrossRef
61.
go back to reference Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27:2616–21.PubMedCrossRef Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27:2616–21.PubMedCrossRef
62.
go back to reference Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32:1308–19.PubMedCrossRef Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32:1308–19.PubMedCrossRef
63.
go back to reference Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–73.PubMedCrossRef Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–73.PubMedCrossRef
64.
go back to reference Carratalá-Munuera MC, Gil-Guillen VF, Orozco-Beltrán D, et al. Barriers associated with poor control in Spanish diabetic patients. A consensus study. Int J Clin Pract 2013. doi:10.1111/ijcp.12160. Carratalá-Munuera MC, Gil-Guillen VF, Orozco-Beltrán D, et al. Barriers associated with poor control in Spanish diabetic patients. A consensus study. Int J Clin Pract 2013. doi:10.​1111/​ijcp.​12160.
65.
go back to reference Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36:381–8.PubMedCrossRef Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36:381–8.PubMedCrossRef
66.
go back to reference Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428–33.PubMedCentralPubMedCrossRef Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428–33.PubMedCentralPubMedCrossRef
67.
go back to reference Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.PubMedCentralPubMedCrossRef Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.PubMedCentralPubMedCrossRef
68.
go back to reference Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27:2149–53.PubMedCrossRef Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27:2149–53.PubMedCrossRef
69.
70.
go back to reference Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRef Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRef
71.
go back to reference Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab. 2009;11:527–33.PubMedCrossRef Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab. 2009;11:527–33.PubMedCrossRef
72.
go back to reference Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–68.PubMedCrossRef Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–68.PubMedCrossRef
73.
go back to reference Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–907.PubMedCrossRef Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–907.PubMedCrossRef
74.
go back to reference Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–77.PubMedCrossRef Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–77.PubMedCrossRef
75.
go back to reference Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabeteic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29:26–40.PubMedCrossRef Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabeteic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29:26–40.PubMedCrossRef
76.
go back to reference Dezii CM, Kawabata H, Tran M. Effects of once daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68–71.PubMed Dezii CM, Kawabata H, Tran M. Effects of once daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68–71.PubMed
77.
go back to reference Guillausseau PJ. Compliance and optimization of oral antidiabetic therapy: a longitudinal study. Presse Med. 2004;33:156–60.PubMedCrossRef Guillausseau PJ. Compliance and optimization of oral antidiabetic therapy: a longitudinal study. Presse Med. 2004;33:156–60.PubMedCrossRef
78.
go back to reference Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011;65:165–71.PubMedCrossRef Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011;65:165–71.PubMedCrossRef
79.
go back to reference Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.PubMed Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.PubMed
80.
go back to reference Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–95.PubMedCrossRef Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–95.PubMedCrossRef
81.
go back to reference Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61:928–32.PubMedCrossRef Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61:928–32.PubMedCrossRef
82.
go back to reference Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–61.PubMedCrossRef Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–61.PubMedCrossRef
83.
go back to reference Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging. 2011;28:249–55.PubMedCrossRef Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging. 2011;28:249–55.PubMedCrossRef
84.
go back to reference Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–9.PubMedCrossRef Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–9.PubMedCrossRef
85.
go back to reference Loke YK, Hinz I, Wang X, Salter C. Systematic review of consistency between adherence to cardiovascular or diabetes medication and health literacy in older adults. Ann Pharmacother. 2012;46:863–72.PubMedCrossRef Loke YK, Hinz I, Wang X, Salter C. Systematic review of consistency between adherence to cardiovascular or diabetes medication and health literacy in older adults. Ann Pharmacother. 2012;46:863–72.PubMedCrossRef
86.
go back to reference Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16:43–9.PubMedCentralPubMed Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16:43–9.PubMedCentralPubMed
87.
go back to reference Chen CC, Tseng CH, Cheng SH. Continuity of care, medication adherence, and health outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care. 2013;51:231–7.PubMedCrossRef Chen CC, Tseng CH, Cheng SH. Continuity of care, medication adherence, and health outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care. 2013;51:231–7.PubMedCrossRef
88.
go back to reference Chu HY, Chen CC, Cheng SH. Continuity of care, potentially inappropriate medication, and health care outcomes among the elderly: evidence from a longitudinal analysis in Taiwan. Med Care. 2012;50:1002–9.PubMedCrossRef Chu HY, Chen CC, Cheng SH. Continuity of care, potentially inappropriate medication, and health care outcomes among the elderly: evidence from a longitudinal analysis in Taiwan. Med Care. 2012;50:1002–9.PubMedCrossRef
89.
go back to reference Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011;34:2–7.PubMedCentralPubMedCrossRef Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011;34:2–7.PubMedCentralPubMedCrossRef
90.
go back to reference Morrow DG, Conner-Garcia T, Graumlich JF, et al. An EMR-based tool to support collaborative planning for medication use among adults with diabetes: design of a multi-site randomized control trial. Contemp Clin Trials. 2012;33:1023–32.PubMedCentralPubMedCrossRef Morrow DG, Conner-Garcia T, Graumlich JF, et al. An EMR-based tool to support collaborative planning for medication use among adults with diabetes: design of a multi-site randomized control trial. Contemp Clin Trials. 2012;33:1023–32.PubMedCentralPubMedCrossRef
91.
go back to reference Lin YH, Chen RR, Guo SH, Chang HY, Chang HK. Developing a web 2.0 diabetes care support system with evaluation from care provider perspectives. J Med Syst. 2012;36:2085–95.PubMedCrossRef Lin YH, Chen RR, Guo SH, Chang HY, Chang HK. Developing a web 2.0 diabetes care support system with evaluation from care provider perspectives. J Med Syst. 2012;36:2085–95.PubMedCrossRef
92.
go back to reference Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence. 2012;6:653–61.PubMedCentralPubMedCrossRef Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence. 2012;6:653–61.PubMedCentralPubMedCrossRef
93.
go back to reference Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf. 2008;17:1091–9.PubMedCrossRef Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf. 2008;17:1091–9.PubMedCrossRef
94.
go back to reference Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951–9.PubMedCrossRef Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951–9.PubMedCrossRef
95.
go back to reference Gibson TB, Song X, Alemayehu B, Wang SS, Wadell JL, Bouchard JR, Forma F. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2012;16:589–600. Gibson TB, Song X, Alemayehu B, Wang SS, Wadell JL, Bouchard JR, Forma F. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2012;16:589–600.
96.
go back to reference Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13:846–52.PubMedCrossRef Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13:846–52.PubMedCrossRef
97.
go back to reference Giuffrida A, Gravelle H. Paying patients to comply: an economic analysis. Health Econ. 1998;7:569–79.PubMedCrossRef Giuffrida A, Gravelle H. Paying patients to comply: an economic analysis. Health Econ. 1998;7:569–79.PubMedCrossRef
98.
go back to reference Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012;15:404–11.PubMedCrossRef Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012;15:404–11.PubMedCrossRef
Metadata
Title
Adherence to Therapies in Patients with Type 2 Diabetes
Authors
Luis-Emilio García-Pérez
María Álvarez
Tatiana Dilla
Vicente Gil-Guillén
Domingo Orozco-Beltrán
Publication date
01-12-2013
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2013
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-013-0034-y

Other articles of this Issue 2/2013

Diabetes Therapy 2/2013 Go to the issue